NewsBenzingaCorvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis Suppurativa Corvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis Suppurativa Benzinga 2026.09.30 20:07 (GMT+0) Open on Benzinga Other news Tolan snags $30M for its AI companion that helps users navigate life Replika’s founder built the AI assistant she pitched at Disrupt 12 years ago Tenstorrent hits $6.2B valuation to scale open-weight AI chips Homebuilder Sentiment Hits 2012 Lows As Stocks Trade Like They Did During COVID-19 Pandemic Rain Says Western Union's Stablecard Is Live in 37 Markets FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated
